Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 4/20 | 0.61 |
| ▸ | FPR2 | P25090 | 4/20 | 0.61 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4592799 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL17202476 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39528 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL4969844 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL9903983 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| N-Formylmethionyl-Leucylphenylalanine SCHEMBL39529 | 1.00 | FPR1 (0.61) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL27066372 | 0.99 | FPR1 (0.60) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL2413701 | 0.99 | FPR1 (0.60) | FPR1FPR2LTA4HMMEMMP2 | |
| SCHEMBL27066369 | 0.94 | FPR1 (0.56) | FPR1FPR2 | |
| SCHEMBL27066397 | 0.94 | FPR1 (0.56) | FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030190368-A1 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-09 | — | — | US | disclosed |
| EP-1062323-A2 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | Cell Activation, Inc. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046367-A2 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | CELL ACTIVATION, INC. (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190368-A1 | METHODS OF DIAGNOSIS AND TRIAGE USING CELL ACTIVATION MEASURES | SERPINB1, PLAT, SERPINE1 | FPR1 299/4885FPR2 568/4885LTA4H 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.